Blog

LACNETS was busy learning from experts and making connections at the 2024 North American Neuroendocrine Tumor Society (NANETS) Annual...

On November 9th, LACNETS held its 2024 NET Cancer Day Symposium in Santa Monica, California, to recognize and celebrate World NET Cancer...

On Saturday, September 21, 2024, over 50 people living with or supporting those living with neuroendocrine cancer gathered for a Regional...

LACNETS participated in INCA’s 12th annual Global NET Patient Advocate Summit in Segovia, Spain with 24 other Patient Advocacy...

Dr. Jennifer Chan from Dana Farber Cancer Institute announces the updated findings On Sept 16, 2024, LACNETS interviewed incoming NANETS...

Neuroendocrine cancer patients often have a variety of available treatment options. Since this cancer behaves differently from other...

Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients...

On April 23, 2024, the Food and Drug Administration approved lutetium Lu 177 dotatate (Lutathera®, Advanced Accelerator Applications USA,...

by Shane Peters, NET Caregiver, NETCONNECT Mentor Shane also wrote the blog post, “Scan Results: To Check or Not to Check.” “Make sure to...

The NETTER-2 phase 3 trial results show Lutathera® may be offered as first-line treatment for newly diagnosed grade 2 and 3 advanced...